Antares' (ATRS) Vibex QuickShot auto injector restored and maintained testosterone levels in a Phase II study of 29 patients. The testosterone-replacement market was worth $2.8B in sales in 2013.

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX ...

EWING, N.J., May 16, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) announced that data from its Phase 3 study of the pharmacokinetics and safety of subcutaneous testosterone enanthate ...

IRVINE, Dec. 27, 2025 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not constitute medical advice. Testosterone replacement therapy requires evaluation and ...

Every item on this page was chosen by an ELLE editor. We may earn commission on some of the items you choose to buy. For those who need it—men who have low levels of testosterone with symptoms such as ...

(MENAFN- GlobeNewsWire - Nasdaq) Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research indicates for men evaluating prescription ...

* Antares Pharma Inc - submitted a new drug application (nda) to U.S. Food And Drug Administration (FDA) for quickshot testosterone Sign up here. * Antares Pharma Inc - quickshot testosterone auto ...